ID   LNCaP-34
AC   CVCL_B414
DR   BTO; BTO:0005045
DR   cancercelllines; CVCL_B414
DR   Wikidata; Q54902829
RX   PubMed=16908524;
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line).
CC   Transfected with: HGNC; 5155; HPN.
CC   Derived from site: Metastatic; Left supraclavicular lymph node; UBERON=UBERON_8480056.
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1379 ! LNCaP clone FGC
SX   Male
AG   50Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 05-10-23; Version: 19
//
RX   PubMed=16908524; DOI=10.1074/jbc.M605440200;
RA   Moran P., Li W., Fan B., Vij R., Eigenbrot C., Kirchhofer D.;
RT   "Pro-urokinase-type plasminogen activator is a substrate for hepsin.";
RL   J. Biol. Chem. 281:30439-30446(2006).
//